39th Annual Course: Advancing Cardiovascular Medicine with Evidence-Based Findings

This distinguished course brings together renowned experts in cardiology to present the latest evidence-based findings in cardiovascular medicine, focusing on topics that have emerged in the last one to two years and are transforming clinical practice.

Course Objectives:

• Providing the best management of coronary heart disease, hypertension, lipid disorders, diabetes, systolic and diastolic heart failure, atrial fibrillation and flutter, STEMI and non-STEMI, and thromboembolic disease
• Refining considerations for atrial fibrillation, atrial flutter, and ventricular tachycardia ablation
• Applying the best considerations of surgical revascularization or percutaneous intervention for management of coronary heart disease
• Recognizing risk stratification of cardiovascular disease
• Optimizing the management of ascending thoracic aorta disease, pulmonary embolism, cardiac amyloidosis, and endocarditis
• Recognizing the genetic basis of cardiovascular diseases and the importance of deep empathy in patient interactions
• Understanding the connection between the mind and the heart, and the role of air pollution as a risk factor for cardiovascular diseases

Target Audience:

This course is designed for cardiovascular specialists, practicing cardiologists, internists, family physicians, and other healthcare professionals seeking to stay up-to-date with the latest advances in cardiovascular medicine.

Course Outline:

Friday, December 2, 2022

• 7:00 a.m. – Registration and Continental Breakfast
• 8:10 a.m. – Welcome and Symposium Overview by Peter Ganz, MD
• Session: Frontiers in Cardiology: Genetics, Artificial Intelligence, and Deep Empathy
• 8:15 a.m. – The Mind-Heart Connection: Stress and Trauma as Cardiovascular Risk Factors by Ahmed Tawakol, MD
• 8:55 a.m. – Artificial Intelligence in Cardiology by Geoff Tison, MD, MPH
• 9:35 a.m. – Ascending Thoracic Aortic Aneurysms: Evaluation, Management, and Genetic Testing by Lisa Wilsbacher, MD, PhD
• 10:15 a.m. – Coffee Break
• 10:30 a.m. – Update on Transthyretin Amyloidosis by Mandar Aras, MD, PhD
• 11:10 a.m. – Gene Targeting for Cardiometabolic Diseases – Where are We? by John Chorba, MD
• 11:50 a.m. – Elliot Rapaport Keynote Lecture: High Performance with Deep Empathy Medicine by Eric Topol, MD
• 12:40 p.m. – Lunch (on Your Own)
• Session: State-of-the-Art: Cardiovascular Interventions
• 2:00 p.m. – New Approaches to Pulmonary Embolism by Gregory Piazza, MD, MS
• 2:40 p.m. – Physiological Assessment of Coronary Stenosis Severity by CT Angiography and in the Cath Lab by William Fearon, MD
• 3:20 p.m. – Expanding Options in the Management of Endocarditis by Amy Fiedler, MD, MS and Ann Bolger, MD
• 4:00 p.m. – Coffee Break
• 4:15 p.m. – Surgical Approaches to Advanced Heart Failure by Jason Smith, MD
• 4:55 p.m. – Revascularization in Stable Coronary Disease: Sorting through the Evidence by Jeffrey Zimmet, MD, PhD
• 5:35 p.m. – Adjourn

Saturday, December 3, 2022

• 7:30 a.m. – Continental Breakfast
• 8:05 a.m. – Announcements by Peter Ganz, MD
• Session: Advances and Controversies in Electrophysiology
• 8:10 a.m. – Defining Sudden Cardiac Death in 2022 by Zian Tseng, MD, MAS
• 8:50 a.m. – ECG Findings Suggesting High Arrhythmic Risk by Melvin Scheinman, MD
• 9:30 a.m. – Debate: AFib Ablation Should be First Line Therapy in Patients with Symptomatic AFib by Adam Lee, MD and Tommy Dewland, MD
• 10:10 a.m. – Coffee Break
• 10:25 a.m. – Advances in Cardiac Imaging for Arrhythmia Etiology, Prognosis, and Therapy by Edward Gerstenfeld, MD, MS
• 11:05 a.m. – The Effect of Alcohol, Exercise, and Lifestyle on Atrial Fibrillation by Gregory Marcus, MD, MAS
• 11:45 a.m. – Interventions for Novel/Genetic Arrhythmias by Vasanth Vedantham, MD, PhD
• 12:25 p.m. – Debate: Prophylactic Primary Prevention ICD in Dilated Cardiomyopathy with Heart Failure by Byron Lee, MD, MS and Joshua Moss, MD, MS
• 1:05 p.m. – Lunch (on Your Own)
• Session: Managing Heart Failure
• 2:20 p.m. – Cardiogenic Shock by Jaya Mallidi, MD
• 3:00 p.m. – New Heart Failure Guidelines for HFrEF by Jonathan Davis, MD, MPH
• 3:40 p.m. – New Heart Failure Guidelines for HFpEF by Jonathan Davis, MD, MPH
• 4:20 p.m. – Coffee Break
• 4:35 p.m. – Polypharmacy and Medication Costs for Guideline Directed Medical Therapy for HFrEF by Anusha McNamara, PharmD and Rose Pavlakos, PharmD
• 5:15 p.m. – Remote Monitoring of Patients with Cardiovascular Diseases by Liviu Klein, MD, MS
• 5:55 p.m. – Adjourn

Sunday, December 4, 2022

• 7:30 a.m. – Continental Breakfast
• 8:00 a.m. – Announcements by Peter Ganz, MD
• Session: Managing Cardiovascular Risk
• 8:05 a.m. – The Effect of Salt and Salt Substitutes Consumption on Clinical Outcomes in Hypertension and Heart Failure by Michael Crawford, MD
• 8:45 a.m. – Managing Cardiovascular Risk in the Elderly by Carlin Long, MD
• 9:25 a.m. – Current Cholesterol Guidelines: Controversies and Agreements by Peter Ganz, MD
• 10:05 a.m. – Where Are We with Non-Statin Lipid Modifying Therapy? by Jorge Plutzky, MD
• 10:45 a.m. – Management of Cardiovascular Risk and Chronic Kidney Disease Progression with Patients with Diabetes by Lisa Murphy, MD, PhD
• 11:25 a.m. – Impact of Air Pollution on Cardiovascular Outcomes by Karol Watson, MD, PhD
• 12:05 p.m. – Adjourn